Arenaviridae

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Buchmeier, Michael J ^a   De La Torre, Juan Carlos ^b   Peters, Clarence J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974682784     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (240)

1. Adair CV, Gauld RL, Smadel JE. Aesptic meningitis, a disease of diverse etiology: clinical and etiologic studies on 854 cases. Ann Int Med 1953;39:675-704.
2. Agnihothram SS, York J, Nunberg JH. Role of the stable signal peptide and cytoplasmic domain of G2 in regulating intracellular transport of the Junin virus envelope glycoprotein complex. J Virol 2006;80:5189-5198.
3. Albarino CG, Bergeron E, Erickson BR, et al. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing. J Virol 2009;83:5606-5614.
4. Ambrosio AM, Enria DA, Maiztegui JI. Junin virus isolation from lympho-mononuclear cells of patients with Argentine hemorrhagic fever. Intervirology 1986;25:97-102.
5. Anonymous. Imported Lassa fever-New Jersey, 2004. MMWR Morb Mortal Wkly Rep 2004;53:894-897.
6. Anonymous. Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. MMWR Morb Mortal Wkly Rep 2005;54:799-801.
7. Armstrong C, Lillie RD. Experimental lymphocytic choriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1933 St. Loius encephalitis epidemic. Publ Health Rep 1934;49:1019-1027.
8. Baldridge JR, Buchmeier MJ. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J Virol 1992;66:4252-4257.
9. Baldridge JR, McGraw TS, Paoletti A, et al. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J Virol 1997;71:755-758.
10. Bannister BA. Stringent precautions are advisable when caring for patients with viral haemorrhagic fevers. Rev Med Virol 1993;3:3-6.
11. Barry M, Russi M, Armstrong L, et al. Treatment of a laboratory-acquired Sabia virus infection. New Eng J Med 1995;333:294-296.
12. Barton LL, Budd SC, Morfitt WS, et al. Congenital lymphocytic choriomeningitis virus infection in twins. Pediatr Infect Dis J 1993;12:942-946.
13. Barton LL, Mets MB, Beauchamp CL. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am J Obstet Gynecol 2002;187:1715-1716.
14. Barton LL, Peters CJ, Ksiazek TG. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. Emerg Infect Dis 1995;1:152-153.
15. Bausch DG, Demby AH, Coulibaly M, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 2001;1:269-281.
16. Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa Fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent antibody test, and virus isolation. J Clin Microbiol 2000;38:2670-2677.
17. Bechtel RT, Haught KA, Mets MB. Lymphocytic choriomeningitis virus: a new addition to the TORCH evaluation. Arch Ophthalmol 1997;115:680-681.
18. Bergthaler A, Gerber NU, Merkler D, et al. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog 2006;2:e51.
19. Biggar RJ, Woodall JP, Walter PD, et al. Lymphocytic choriomeningitis outbreak associated with pet hamsters. Fifty-seven cases from New York State. JAMA 1975;232:494-500.
20. Blakqori G, Weber F. Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs. J Virol 2005;79:10420-10428.
21. Blanc G, Bruneau B, Delage B, et al. Pneumopathy of the guinea pig and lymphocytic choriomeningitis. Bull Acad Nat Med Paris 1951;135:255-262.
22. Bolken TC, Laquerre S, Zhang Y, et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res 2006;69:86-97.
23. Botten J, Sidney J, Mothe BR, et al. Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system. Microbiol Mol Biol Rev 2010;74:157-170.
24. Botten J, Whitton JL, Barrowman P, et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 2010;84:9947-9956.
25. Boxaca MC, d. Guerrero LB, Parodi AS, et al. Viremia in Argentinian hemorrhagic fever. Rev Asoc Med Argent 1965;79:230-238.
26. Bredenbeek PJ, Molenkamp R, Spaan WJ, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006;345:299-304.
27. Brunotte L, Lelke M, Hass M, et al. Domain structure of Lassa virus L protein. J Virol 2011;85:324-333.
28. Bruns M, Cihak J, Muller G, et al. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virol 1983;130:247-251.
29. Buchmeier M, Adam E, Rawls WE. Serological evidence of infection by Pichinde virus among laboratory workers. Infect Immun 1974;9:821-823.
30. Buchmeier MJ, Peters CJ, de la Torre JC. Arenaviridae: the virus and their replication. Fields Virology 2007;2:1792-1827.
31. Buchmeier MJ, Welsh RM, Dutko FJ, et al. The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol 1980;30:275-331.
32. Buchmeier MJ, Zajac AJ. Lymphocytic Choriomenigitis Virus. Chichester, Sussex, U.K: John Wiley & Sons Ltd; 1999.
33. Byrd RG, Cone LA, Commess BC, et al. Fatal illness associated with a New World arenavirus-California, 1999-2000. Morb Mortal Wkly Rep 2000;49:709-711.
34. Calisher CH, Tzianabos T, Lord RD, et al. Tamiami virus, a new member of the Tacaribe group. Am J Trop Med Hyg 1970;19:520-526.
35. Cao W, Henry MD, Borrow P, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998;282:2079-2081.
36. Carey DE, Kemp GE, White HA, et al. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 1972;66:402-408.
37. Carlton JG, Martin-Serrano J. The ESCRT machinery: new functions in viral and cellular biology. Biochem Soc Trans 2009;37:195-199.
38. Carrion R Jr, Patterson JL, Johnson C, et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007;25:4093-4102.
39. Charrel RN, de Lamballerie X, Emonet S. Phylogeny of the genus Arenavirus. Curr Opin Microbiol 2008;11:362-368.
40. Chastel C, Bosshard S, Le Goff F, et al. Infection transplacentaire par le virus de la choriomeningite lymphocytaire. Resultats d'une enquete serologique retrospective en France. Nouv Presse Med 1978;7:1089-1092.
41. Chen M, Lan S, Ou R, et al. Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. J Gen Virol 2008;89:1421-1433.
42. Connolly BM, Jensen AB, Peters CJ, et al. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am J Trop Med Hyg 1993;49:10-24.
43. Cornu TI, de la Torre JC. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol 2002;76:6678-6688.
44. Cornu TI, DeLaTorre JC. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J Virol 2001:9415-9426.
45. Cornu TI, Feldmann H, de la Torre JC. Cells expressing the RING finger Z protein are resistant to arenavirus infection. J Virol 2004;78:2979-2983.
46. Cummins D, Bennett D, Fisher-Hoch SP, et al. Electrocardiographic abnormalities in patients with Lassa fever. J Trop Med Hyg 1989;92:350-355.
47. Cummins D, McCormick JB, Bennett D, et al. Acute sensorineural deafness in Lassa fever. JAMA 1990;264:2093-2096.
48. Damonte EB, Coto CE. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv Virus Res 2002;58:125-155.
49. De Bracco MM, Rimoldi MT, Cossio PM, et al. Argentine hemorrhagic fever. Alterations of the complement system and anti-Junin-virus humoral response. N Engl J Med 1978;299:216-221.
50. De Manzione N, Salas RA, Paredes H. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis 1998;26:308-313.
51. Deibel R, Schryver GD. Viral antibody in the cerebrospinal fluid of patients with acute central nervous system infections. J Clin Microbiol 1976;3:397-401.
52. Deibel R, Woodall JP, Decher WJ, et al. Lymphocytic choriomeningitis virus in man. Serologic evidence of association with pet hamsters. JAMA 1975;232:501-504.
53. Demby AH, Chamberlain J, Brown DW, et al. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 1994;32:2898-2903.
54. Djavani M, Rodas J, Lukashevich IS, et al. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J Virol 2001;75:6204-6208.
55. Downs WG, Anderson CR, Spence L, et al. Tacaribe virus, a new agent isolated from Artibeus bats and mosquitoes in Tinidad, West Indies. Am J Trop Med Hyg 1963;12:640-646.
56. Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group [see comments]. N Engl J Med 1994;330:949-955.
57. Eddy GA, Wagner FS, Scott SK, et al. Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin). Bull World Health Organ 1975;52:723-727.
58. Elliott LH, McCormick JB, Johnson KM. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 1982;16:704-708.
59. Emonet S, Retornaz K, Gonzalez JP, et al. Mouse-to-human transmission of variant lymphocytic choriomeningitis virus. Emerg Infect Dis 2007;13:472-475.
60. Emonet SF, de la Torre JC, Domingo E, et al. Arenavirus genetic diversity and its biological implications. Infect Genet Evol 2009;9:417-429.
61. Emonet SF, Garidou L, McGavern DB, et al. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A 2009;106:3473-3478.
62. Emonet SF, Seregin AV, Yun NE, et al. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J Virol 2011;85(4):1473-1483.
63. Enria DA, Barrera Oro JG. Junin virus vaccines. Curr Top Microbiol Immunol 2002;263:239-261.
64. Enria DA, Briggiler AM, Fernandez NJ, et al. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2:255-256.
65. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31.
66. Eschli B, Quirin K, Wepf A, et al. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J Virol 2006;80:5897-5907.
67. Farmer TW, Janeway CA. Infections with the virus of lymphocytic choriomeningitis. Medicine 1942;21:1-64.
68. Fearns R, Peeples ME, Collins PL. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 1997;236:188-201.
69. Ferencz A, Binder L, Telegdy L, Simon M. [Lymphocytic choriomeningitis virus infections in adults during 1971-1976]. Orv Hetil 1979;120:1563-1567.
70. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006;354:2235-2249.
71. Fisher-Hoch SP. Stringent precautions are not advisable when caring for patients with viral haemorrhagic fevers. Re Med Virol 1993;3:7-13.
72. Fisher-Hoch SP, Hutwagner L, Brown B, et al. Effective vaccine for lassa fever. J Virol 2000;74:6777-6783.
73. Flatz L, Bergthaler A, de la Torre JC, et al. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A 2006;103:4663-4668.
74. Flatz L, Hegazy AN, Bergthaler A, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 2010;16:339-345.
75. Frame JD. Surveillance of Lassa fever in missionaries stationed in West Africa. Bull World Health Organ 1975;52:593-598.
76. Frame JD, Baldwin JM Jr, Gocke DJ, et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970;19:670-676.
77. Frame JD, Jahrling PB, Yalley-Ogunro JE, et al. Endemic Lassa fever in Liberia. II. Serological and virological findings in hospital patients. Trans R Soc Trop Med Hyg 1984;78:656-660.
78. Freed EO. Viral late domains. J Virol 2002;76:4679-4687.
79. Fulhorst CF, Bowen MD, Ksiazek TG, et al. Isolation and characterization of Whitewater Arroyo virus, a novel North American arenavirus. Virol 1996;224:114-120.
80. Gallaher WR, DiSimone C, Buchmeier MJ. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol 2001;1:1.
81. Garcia Franco S, Ambrosio AM, Feuillade MR, et al. Evaluation of an enzyme-linked immunosorbent assay for quantitation of antibodies to Junin virus in human sera. J Virol Methods 1988;19:299-306.
82. Garcin D, Kolakofsky D. A novel mechanism for the initiation of Tacaribe arenavirus genome replication. J Virol 1990;64:6196-6203.
83. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005;2:e183.
84. Gonzalez JP, Emonet S, de Lamballerie X, et al. Arenaviruses. Curr Top Microbiol Immunol 2007;315:253-288.
85. Groseth A, Feldmann H, Theriault S, et al. RNA polymerase I-driven minigenome system for Ebola viruses. J Virol 2005;79:4425-4433.
86. Halfmann P, Kim JH, Ebihara H, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A 2008;105:1129-1133.
87. Hass M, Golnitz U, Muller S, et al. Replicon system for Lassa virus. J Virol 2004;78:13793-13803.
88. Hass M, Lelke M, Busch C, et al. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. J Virol 2008;82:10207-10217.
89. Hass M, Westerkofsky M, Muller S, et al. Mutational analysis of the lassa virus promoter. J Virol 2006;80:12414-12419.
90. Hastie KM, Kimberlin CR, Zandonatti MA, et al. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 2011;108:2396-2401.
91. Hawkins JL, Robbins MD, Warren LC, et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther 2008;326:801-808.
92. Hay BA, Abrams B, Zumbrunn AY, et al. Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg Med Chem Lett 2007;17:4411-4414.
93. Hirabayashi Y, Oka S, Goto H, et al. An imported case of Lassa fever with late appearance of polyserositis. J Infect Dis 1988;158:872-875.
94. Hirsch E. Sensorineural deafness and labyrinth damage due to lymphocytic choriomeningitis. Arch Otolaryngol 1976;102:499-500.
95. Hirsch MS, Moellering RC Jr, Pope HG, et al. Lymphocytic-choriomeningitis-virus infection traced to a pet hamster. N Engl J Med 1974;291:610-612.
96. Horton J, Hotchin JE, Olson KB, et al. The effects of MP virus infection in lymphoma. Cancer Res 1971;31:1066-1068.
97. Hotchin J, Sikora E. Laboratory diagnosis of lymphocytic choriomeningitis. Bull World Health Organ 1975;52:555-559.
98. Ivanov AP, Rezapkin GV, Dzagurova TK, et al. Indirect solid-phase immunosorbent assay for detection of arenavirus antigens and antibodies. Acta Virol 1984;28:240-245.
99. Jahrling PB, Hesse RA, Eddy GA, et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980;141:580-589.
100. Jahrling PB, Niklasson BS, McCormick JB. Early diagnosis of human Lassa fever by ELISA detection of antigen and antibody. Lancet 1985;1:250-252.
101. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 1984;44:528-533.
102. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984;149:420-427.
103. Jasenosky LD, Neumann G, Lukashevich I, et al. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001;75:5205-5214.
104. Johnson KM, Halstead SB, Cohen SN. Hemorrhagic fevers of Southeast Asia and South America: a comparative appraisal. Prog Med Virol 1967;9:105-158.
105. Johnson KM, McCormick JB, Webb PA, et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987;155:456-464.
106. Johnson KM, Wiebenga NH, Mackenzie RB, et al. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med 1965;118:113-118.
107. Justines G, Johnson KM. Use of oral swabs for detection of Machupo-virus infection in rodents. Am J Trop Med Hyg 1968;17:788-790.
108. Kawaoka YE. Biology of negative strand RNA viruses: the power of reverse genetics. Curr Top Microbiol Immunol 2004;283.
109. Kenyon RH, Canonico PG, Green DE, et al. Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother 1986;29:521-523.
110. Kenyon RH, Green DE, Eddy GA, et al. Treatment of Junin virus-infected guinea pigs with immune serum: development of late neurological disease. J Med Virol 1986;20:207-218.
111. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 1997;24:718-722.
112. Komrower GM, Williams BL, Stones PB. Lymphocytic choriomeningitis in the newborn. Lancet 1955:268(6866)697.
113. Kotturi MF, Botten J, Sidney J, et al. A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog 2009;5:e1000695.
114. Kranzusch PJ, Schenk AD, Rahmeh AA, et al. Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A 2010;107:20069-20074.
115. Kunz S, Borrow P, Oldstone MB. Receptor structure, binding, and cell entry of arenaviruses. Curr Top Microbiol Immunol 2002;262:111-137.
116. Kunz S, Edelmann KH, de la Torre J-C, et al. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 2003;314(1):168-178.
117. Lan S, McLay Schelde L, Wang J, et al. Development of infectious clones for virulent and avirulent Pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol 2009;83:6357-6362.
118. Larsen PD, Chartrand SA, Tomashek KM, et al. Hydrocephalus complicating lymphocytic choriomeningitis virus infection. Pediatr Infect Dis J 1993;12:528-531.
119. Lecompte E, ter Meulen J, Emonet S, et al. Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 2007;364:178-183.
120. Lee AM, Rojek JM, Spiropoulou CF, et al. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem 2008;283:18734-18742.
121. Lee JS, Hadjipanayis AG, Parker MD. Viral vectors for use in the development of biodefense vaccines. Adv Drug Deliv Rev 2005;57:1293-1314.
122. Lee KJ, Novella IS, Teng MN, et al. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol 2000;74:3470-3477.
123. Lehmann-Grube F, Kallay M, Ibscher B, et al. Serologic diagnosis of human infections with lymphocytic choriomeningitis virus: comparative evaluation of seven methods. J Med Virol 1979;4:125-136.
124. Lelke M, Brunotte L, Busch C, et al. An N-terminal region of Lassa virus L protein plays a critical role in transcription but not replication of the virus genome. J Virol 2010;84:1934-1944.
125. Lenz O, Meulen J, Klenk HD, et al. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. PNAS 2001;98:12701-12705.
126. Levis SC, Saavedra MC, Ceccoli C, et al. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 1985;5:383-389.
127. Lewis VJ, Walter PD, Thacker WL, et al. Comparison of three tests for the serological diagnosis of lymphocytic choriomeningitis virus infection. J Clin Microbiol 1975;2:193-197.
128. Liang Y, Lan S, Ly H. Molecular determinants of Pichinde virus infection of guinea pigs-a small animal model system for arenaviral hemorrhagic fevers. Ann N Y Acad Sci 2009;1171(Suppl 1):E65-E74.
129. Liao BS, Byl FM, Adour KK. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause [see comments]. Otolaryngol Head Neck Surg 1992;106:226-229.
130. Lisieux T, Coimbra M, Nassar ES, et al. New arenavirus isolated in Brazil. Lancet 1994;343:391-392.
131. Lopez N, Jacamo R, Franze-Fernandez MT. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J Virol 2001;75:12241-12251.
132. Lowen AC, Noonan C, McLees A, et al. Efficient bunyavirus rescue from cloned cDNA. Virology 2004;330:493-500.
133. Lucia HL, Coppenhaver DH, Baron S. Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res 1989;12:279-292.
134. Mackenzie RB. Epidemiology of Machupo virus infection. I. Pattern of human infection, San Joaquin, Bolivia, 1962-1964. Am J Trop Med Hyg 1965;14:808-813.
135. Maiztegui JI. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 1975;52:567-575.
136. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979;2:1216-1217.
137. Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998;177:277-283.
138. Martinez MG, Cordo SM, Candurra NA. Characterization of Junin arenavirus cell entry. J Gen Virol 2007;88:1776-1784.
139. Martinez SSM, Grazioli F, De Garre MEG, et al. Application of immunofluorescence for the diagnosis of Argentine hemorrhagic fever. Ciencia Invest 1966;22:316-319.
140. Martinez-Sobrido L, Emonet S, Giannakas P, et al. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 2009;83:11330-11340.
141. Martinez-Sobrido L, Garcia-Sastre A. Generation of recombinant influenza virus from plasmid DNA. J Vis Exp 2010;42:2057.
142. Martinez-Sobrido L, Giannakas P, Cubitt B, et al. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 2007;81:12696-12703.
143. Martinez-Sobrido L, Zuniga EI, Rosario D, et al. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 2006;80:9192-9199.
144. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr Top Microbiol Immunol 2002;262:75-109.
145. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987;155:445-455.
146. McCormick JB, Walker DH, King IJ, et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986;35:401-407.
147. McCormick JB, Webb PA, Krebs JW, et al. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987;155:437-444.
148. McKee KT Jr, Oro JG, Kuehne AI, et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992;34:154-163.
149. Merkler D, Horvath E, Bruck W, et al. "Viral deja vu" elicits organ-specific immune disease independent of reactivity to self. J Clin Invest 2006;116:1254-1263.
150. Mertens PE, Patton R, Baum JJ, et al. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg 1973;22:780-784.
151. Meyer BJ, de La Torre JC, Southern PJ. Arenaviruses: Genomic RNAs, Transcription, and Replication. In: Oldstone MB, ed. Arenaviruses I, vol. 262. Berlin Heidelberg: Springer-Verlag; 2002:139-149.
152. Meyer HM, Johnson RT, Crawford EP, et al. Central nervous system syndromes of "viral" etiology. Am J Med 1960;29:334-347.
153. Mills JN, Barrera Oro JG, Bressler DS, et al. Characterization of Oliveros Virus, a new member of the Tacaribe complex. Am J Trop Med Hyg 1996;54:399-404.
154. Mills JN, Ellis BA, Childs JE, et al. Prevalence of infection with Junin virus in rodent populations in the epidemic area of Argentine hemorrhagic fever. Am J Trop Med Hyg 1994;51:554-562.
155. Minskaia E, Hertzig T, Gorbalenya AE, et al. Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A 2006;103:5108-5113.
156. Monson MH, Cole AK, Frame JD, et al. Pediatric Lassa fever: a review of 33 Liberian cases. Am J Trop Med Hyg 1987;36:408-415.
157. Morin B, Coutard B, Lelke M, et al. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog 2010:6(9):e1001038.
158. Morita E, Sandrin V, McCullough J, et al. ESCRT-III protein requirements for HIV-1 budding. Cell Host Microbe 2011;9:235-242.
159. Muller G, Bruns M, Martinez Peralta L, et al. Lymphocytic choriomeningitis virus. IV. Electron microscopic investigation of the virion. Arch Virol 1983;75:229-242.
160. Murphy FA, Webb PA, Johnson KM, et al. Arenoviruses in Vero cells: ultrastructural studies. J Virol 1970;6:507-518.
161. Neuman BW, Adair BD, Burns JW, et al. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. J Virol 2005;79:3822-3830.
162. Neumann G, Kawaoka Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. Curr Top Microbiol Immunol 2004;283:43-60.
163. Niklasson BS, Jahrling PB, Peters CJ. Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay. J Clin Microbiol 1984;20:239-244.
164. Oldstone MB. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr Top Microbiol Immunol 2002;263:83-117.
165. Oldstone MB, Holmstoen J, Welsh RM Jr. Alterations of acetylcholine enzymes in neuroblastoma cells persistently infected with lymphocytic choriomeningitis virus. J Cell Physiol 1977;91:459-472.
166. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358:991-998.
167. Park JY, Peters CJ, Rollin PE, et al. Development of an RT-PCR assay for diagnosis of lymphocytic choriomeningitis virus (LCMV) infection and its use in a prospective surveillance study. J Med Virol 1997;1997:107-114.
168. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005;107:165-171.
169. Perez M, Craven RC, de la Torre JC. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A 2003;100:12978-12983.
170. Perez M, de la Torre JC. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 2003;77:1184-1194.
171. Perez M, Greenwald DL, de la Torre JC. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol 2004;78:11443-11448.
172. Peters CJ. Lymphocytic choriomeningitis virus-an old enemy up to new tricks. N Engl J Med 2006;354:2208-2211.
173. Peters CJ, Jahrling PB, Liu CT, et al. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987;134:5-68.
174. Peters CJ, Johnson ED, McKee JKT. Filoviruses and management of viral hemorrhagic fevers. In: Belshe R, ed. Textbook of Human Virol. 2nd ed. St. Louis: Mosby Year Book, Inc.; 1991:699-712.
175. Peters CJ, Shelokov A. Viral hemorrhagic fever. In: Kass EH, Platt R, eds. Current Therapy in Infectious Disease, vol. 3. Toronto: B.C. Decker Inc; 1990:355-360.
176. Peters CJ, Webb PA, Johnson KM. Measurement of antibodies to Machupo virus by the indirect fluorescent technique. Proc Soc Exp Biol Med 1973;142:526-531.
177. Pinschewer DD, Perez M, de la Torre JC. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol 2005;79:4519-4526.
178. Pinschewer DD, Perez M, de la Torre JC. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol 2003;77:3882-3887.
179. Pinschewer DD, Perez M, Sanchez AB, et al. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A 2003;100:7895-7900.
180. Pinschewer DD, Schedensack M, Bergthaler A, et al. T cells can mediate viral clearance from ependyma but not from brain parenchyma in a major histocompatibility class I- and perforin-independent manner. Brain 2010;133:1054-1066.
181. Poch O, Sauvaget I, Delarue M, et al. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989;8:3867-3874.
182. Pushko P, Geisbert J, Parker M, et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001;75:11677-11685.
183. Qi X, Lan S, Wang W, et al. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010;468:779-783.
184. Radoshitzky SR, Abraham J, Spiropoulou CF, et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 2007;446:92-96.
185. Rivers TM, Scott TFM. Meningitis in man caused by a filterable virus. Science 1935;81:439-440.
186. Rodriguez-Carreno MP, Nelson MS, Botten J, et al. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 2005;335:87-98.
187. Rojek JM, Kunz S. Cell entry by human pathogenic arenaviruses. Cell Microbiol 2008;10:828-835.
188. Rojek JM, Lee AM, Nguyen N, et al. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J Virol 2008;82:6045-6051.
189. Rojek JM, Pasqual G, Sanchez AB, et al. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J Virol 2010;84:573-584.
190. Rojek JM, Perez M, Kunz S. Cellular entry of lymphocytic choriomeningitis virus. J Virol 2008;82:1505-1517.
191. Rojek JM, Sanchez AB, Nguyen NT, et al. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 2008;82:7677-7687.
192. Rowe WP, Murphy FA, Bergold GH, et al. Arenoviruses: proposed name for a newly defined virus group. J Virol 1970;5:651-652.
193. Ruggiero HR, Cintora FA, Libonatti EJ, et al. Formas nerviosas de la fiebre hemorragica epidemica. Prensa Med Argent 1960;47:1845-1849.
194. Ruo SL, Mitchell SW, Kiley MP, et al. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J Gen Virol 1991;72:549-555.
195. Sabeti PC, Varilly P, Fry B, et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007;449:913-918.
196. Sakai J, Nohturfft A, Goldstein JL, et al. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 1998;273:5785-5793.
197. Sakai J, Rawson Rb, Espenshade PJ, et al. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Molecular Cell 1998;2:505-514.
198. Salas R, de Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever. Lancet 1991;338:1033-1036.
199. Salvato MS. Molecular biology of the prototype arenavirus, lymphocytic choriomeningitis virus. In: Salvato MS, ed. The Arenaviridae. New York: Plenum Press; 1993:133-156.
200. Sanchez A, Pifat DY, Kenyon RH, et al. Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol 1989;70:1125-1132.
201. Sanchez AB, de la Torre JC. Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 2005;79:7262-7268.
202. Sanchez AB, de la Torre JC. Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology 2006;350:370-380.
203. Saunders AA, Ting JP, Meisner J, et al. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol 2007;81:5649-5657.
204. Schmitz H, Kohler B, Laue T, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 2002;4:43-50.
205. Schneider U, Schwemmle M, Staeheli P. Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc Natl Acad Sci U S A 2005;102:3441-3446.
206. Scott TFM, Rivers TM. Meningitis in man caused by a filterable virus. J Exp Med 1936;63:397-434.
207. Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 2006;387:871-877.
208. Shah WA, Peng H, Carbonetto S. Role of non-raft cholesterol in lymphocytic choriomeningitis virus infection via alpha-dystroglycan. J Gen Virol 2006;87:673-678.
209. Sheinbergas MM. Hydrocephalus due to prenatal infection with the lymphocytic choriomeningitis virus. Infection 1976;4:185-191.
210. Sheinbergas MM, Verikene VV, Maslinskas VY, et al. Sepcific immunofluorescent IgG, IgM, and IgA antibodies in lymphocytic choriomeningitis. Acta Virol 1978;22:218-224.
211. Smadel JE, Green RM, Paltauf RM, et al. Lymphocytic choriomeningitis: two human fatalities following an unusual febrile illness. Proc Soc Exp Biol Med 1942;49:683.
212. Smee DF, Gilbert J, Leonhardt JA, et al. Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res 1993;20:57-70.
213. Solbrig MV, McCormick JB. Lassa fever: central nervous system manifestations. J Trop Geograph Neurol 1991;1:23.
214. Southern PJ. Arenaviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al, eds. Feilds Virol. Philadelphia: Lippencott-Raven; 1996:1505-1519.
215. Stenglein MD, Sanders C, Kistler AL, et al. Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents for snake inclusion body disease. MBio 2012:3:e00180-12.
216. Stephen EL, Jones DE, Peters CJ, et al. Ribavirin treatment of Toga-, arena-, bunyavirus infection in subhuman primates and other laboratory animal species. In: Smith RA, Kirkpatrick W, eds. Ribavirin: a Broad Spectrum Antiviral Agent. New York: Academic Press; 1980:169-183.
217. Stinebaugh BJ, Schloeder FX, Johnson KM, et al. Bolivian hemorrhagic fever. A report of four cases. Am J Med 1966;40:217-230.
218. Strecker T, Eichler R, Meulen J, et al. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J Virol 2003;77:10700-10705.
219. Strecker T, Maisa A, Daffis S, et al. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol J 2006;3:93.
220. Tindall GT, Gladstone LA. Hydrocephalus as a sequel to lymphocytic choriomeningitis. Neurology 1957;7:516-518.
221. Trappier SG, Conaty AL, Farrar BB, et al. Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg 1993;49:214-221.
222. Traub E. A filterable virus recovered from white mice. Sci 1935;81:298-299.
223. Traub E. Observations on "late onset disease" and tumor incidence in different strains of laboratory mice infected congenitally with LCM virus. II. Experiments with inbred CBA/J mice. Zentralbl Veterinarmed [B] 1975;22:783-792.
224. Urata S, Yun N, Pasquato A, et al. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol 2011;85(2):795-803.
225. Vanzee BE, Douglas RG, Betts RF, et al. Lymphocytic choriomeningitis in university hospital personnel. Clinical features. Am J Med 1975;58: 803-809.
226. Vasconcelos PFC, Travassos da Rosa APA, Rodrigues SG, et al. Infeccao humana pelo virus SP 114202 (Arenavirus: familia Arenaviridae): aspectos clinicos e laboratoriais de uma nova doenca. Rev Inst Med Trop Sao Paulo 1994;35:521-525.
227. Vela EM, Zhang L, Colpitts TM, et al. Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology 2007;369:1-11.
228. Vieth S, Torda AE, Asper M, et al. Sequence analysis of L RNA of Lassa virus. Virology 2004;318:153-168.
229. Volpon L, Osborne MJ, Capul AA, et al. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proc Natl Acad Sci U S A 2010;107:5441-5446.
230. Walker DH, McCormick JB, Johnson KM, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982;107:349-356.
231. Walker DH, Murphy FA. Pathology and pathogenesis of arenavirus infections. Curr Top Microbiol Immunol 1987;133:89-113.
232. Warkel RL, Rinaldi CF, Bancroft WH, et al. Fatal acute meningoencephalitis due to lymphocytic choriomeningitis virus. Neurology 1973;23:198-203.
233. Wiebenga NH, Shelokov A, Gibbs CJ, et al. Epidemic hemorrhagic fever in Bolivia. II. Demonstration of complement-fixing antibody in patients' sera with Junin virus antigen. Am J Trop Med Hyg 1964;13:626-628.
234. Wright KE, Buchmeier MJ. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J Virol 1991;65:3001-3006.
235. Wright R, Johnson D, Neumann M, et al. Congenital lymphocytic choriomeningitis virus syndrome: a disease that mimics congenital toxoplasmosis or Cytomegalovirus infection. Pediatrics 1997;100:E9.
236. York J, Agnihothram SS, Romanowski V, et al. Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junin arenavirus envelope glycoprotein. Virology 2005;343:267-274.
237. York J, Nunberg JH. Distinct requirements for signal peptidase processing and function in the stable signal peptide subunit of the Junin virus envelope glycoprotein. Virology 2007;359:72-81.
238. York J, Nunberg JH. Role of the stable signal peptide of Junin arenavirus envelope glycoprotein in pH-dependent membrane fusion. J Virol 2006;80:7775-7780.
239. York J, Romanowski V, Lu M, et al. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol 2004;78:10783-10792.
240. Young PR, Howard CR. Fine structure analysis of Pichinde virus nucleocapsids. J Gen Virol 1983;64:833-842.